Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the safety/tolerability of 52 weeks of treatment with QVA149 (110μg indacaterol/50μg glycopyrrolate) once a day on adverse event reporting rate in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD)
Critère d'inclusion
- Chronic Obstructive Pulmonary Disease (COPD)